3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
30
Myelodysplastic Syndromes
26
Hematologic Neoplasms
20
Lymphoma, Non-Hodgkin
19
Multiple Myeloma
18
Lymphoma
18
Recurrence
15
Lymphoma, B-Cell
14
Lymphoma, Large B-Cell, Diffuse
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Burkitt Lymphoma
12
Breast Neoplasms
11
Pancreatic Neoplasms
10
Ovarian Neoplasms
10
Lymphoma, Follicular
10
Neoplasm Metastasis
9
Melanoma
9
Leukemia, Myelomonocytic, Chronic
9
Myeloproliferative Disorders
8
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
7
Leukemia, Biphenotypic, Acute
7
Leukemia
7
Hodgkin Disease
7
Glioblastoma
7
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Osteosarcoma
6
Interventions
dinutuximab
3
Cyclophosphamide
3
Vincristine
2
Topotecan
2
Thiotepa
2
Temozolomide
2
Stem Cell Transplantation
2
Specimen Handling
2
Radiation
2
Platinum
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Isotretinoin
2
Irinotecan
2
Doxorubicin
2
Cisplatin
2
Carboplatin
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
sargramostim
1
lorlatinib
1
fludarabine
1
etoposide phosphate
1
Transurethral Resection of Bladder
1
Razoxane
1
Radiotherapy
1
Proton Therapy
1
Nuclear Medicine Department, Hospital
1
Leukapheresis
1
Influenza Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Ganglioneuroblastoma
×
fludarabine
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled